Literature DB >> 21941087

FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.

Bulbul Pandit1, Andrei L Gartel.   

Abstract

Apoptosis has been widely accepted as the primary mechanism of drug-induced cell death. Recently, a second type of cell death pathway has been demonstrated: autophagy, also called programmed type II cell death. Autophagy is a highly regulated process, by which selected components of a cell are degraded. It primarily functions as a cell survival mechanism under stress. However, persistent stress can also promote extensive autophagy leading to cell death. Forkhead box M1 (FoxM1), an oncogenic transcription factor that is abundantly expressed in a wide range of human cancers. Here we evaluated the role of FoxM1 in sensitivity of human cancer cells to proteasome inhibitor-induced apoptosis and autophagy. We found that FoxM1 knockdown sensitized the human cancer cells to apoptotic cell death induced by proteasome inhibitors, such as, MG132, bortezomib and thiostrepton, while it did not affect the levels of autophagy following treatment with these drugs.
© 2011 Landes Bioscience

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941087      PMCID: PMC3233624          DOI: 10.4161/cc.10.19.17735

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  20 in total

Review 1.  The proteasome: a suitable antineoplastic target.

Authors:  Julian Adams
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

Review 2.  The role of autophagy in cancer development and response to therapy.

Authors:  Yasuko Kondo; Takao Kanzawa; Raymond Sawaya; Seiji Kondo
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

Review 3.  FoxM1: at the crossroads of ageing and cancer.

Authors:  Jamila Laoukili; Marie Stahl; René H Medema
Journal:  Biochim Biophys Acta       Date:  2006-08-30

4.  Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells.

Authors:  Peng-Fei Ge; Ji-Zhou Zhang; Xiao-Fei Wang; Fan-Kai Meng; Wen-Chen Li; Yong-Xin Luan; Feng Ling; Yi-Nan Luo
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

Review 5.  Protein degradation or regulation: Ub the judge.

Authors:  M Hochstrasser
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

Review 6.  Autophagy as a target for anticancer therapy.

Authors:  Filip Janku; David J McConkey; David S Hong; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2011-05-17       Impact factor: 66.675

7.  Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.

Authors:  Aslamuzzaman Kazi; Harshani Lawrence; Wayne C Guida; Mark L McLaughlin; Gregory M Springett; Norbert Berndt; Richard M L Yip; Saïd M Sebti
Journal:  Cell Cycle       Date:  2009-06-20       Impact factor: 4.534

8.  A novel mode of FoxM1 regulation: positive auto-regulatory loop.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Cell Cycle       Date:  2009-06-09       Impact factor: 4.534

9.  FoxM1 is a general target for proteasome inhibitors.

Authors:  Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

10.  Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells.

Authors:  Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more
  20 in total

Review 1.  Signaling of miRNAs-FOXM1 in cancer and potential targeted therapy.

Authors:  Min Shi; Jiujie Cui; Keping Xie
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

2.  Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.

Authors:  Brian Cunniff; Kira Benson; Jason Stumpff; Kheng Newick; Paul Held; Douglas Taatjes; Joy Joseph; Balaraman Kalyanaraman; Nicholas H Heintz
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

3.  Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes.

Authors:  Shuxi Qiao; Sarah D Lamore; Christopher M Cabello; Jessica L Lesson; José L Muñoz-Rodriguez; Georg T Wondrak
Journal:  Biochem Pharmacol       Date:  2012-02-01       Impact factor: 5.858

4.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 5.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

6.  Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.

Authors:  Lin Li; Biao Fan; Lian-Hai Zhang; Xiao-Fang Xing; Xiao-Jing Cheng; Xiao-Hong Wang; Ting Guo; Hong Du; Xian-Zi Wen; Jia-Fu Ji
Journal:  Tumour Biol       Date:  2016-02-01

7.  A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS.

Authors:  Marianna Halasi; Renáta Váraljai; Elizaveta Benevolenskaya; Andrei L Gartel
Journal:  J Biol Chem       Date:  2015-11-11       Impact factor: 5.157

Review 8.  The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review.

Authors:  Anastasios Kyriazoglou; Michalis Liontos; Roubini Zakopoulou; Maria Kaparelou; Anna Tsiara; Alkistis Maria Papatheodoridi; Rebecca Georgakopoulou; Flora Zagouri
Journal:  Breast Care (Basel)       Date:  2020-05-12       Impact factor: 2.860

9.  Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells.

Authors:  Kheng Newick; Brian Cunniff; Kelsey Preston; Paul Held; Jack Arbiser; Harvey Pass; Brooke Mossman; Arti Shukla; Nicholas Heintz
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

10.  The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer.

Authors:  Karan Ulhaka; Kanyanatt Kanokwiroon; Mattaka Khongkow; Rassanee Bissanum; Thanaporn Khunpitak; Pasarat Khongkow
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.